1. The Discovery of the CCR5 Receptor Antagonist, UK-427,857, A New Agent for the Treatment of HIV Infection and AIDS
2. 2B Weatherley, L McFadyen, and P. Milligan, Population analysis of maraviroc phase 1 noncompartmental pharmacokinetic data . In: 15th Meeting of the Population Approach Group Europe. 2006 June 14-16; Brussels, Belgium.
3. 3G Muirhead, A Pozniak, B Gazzard, M Nelson, G Moyle, C Ridgway, R Taylor-Worth, and D Russell . A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of UK-427 857 in HIV+ve subjects (abstract 663) . In: 12th Conference on Retroviruses and Opportunistic Infections. 2005 February 22-25; Boston, MA.
4. SPECIES DIFFERENCES IN THE DISPOSITION OF THE CCR5 ANTAGONIST, UK-427,857, A NEW POTENTIAL TREATMENT FOR HIV
5. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc